Showing 1 - 5 results of 5 for search 'Andrew B Nixon', query time: 0.02s
Refine Results
-
1
Endoglin Targeting: Lessons Learned and Questions That Remain by Yingmiao Liu, Madelon Paauwe, Andrew B. Nixon, Lukas J.A.C. Hawinkels
Published 2020-12-01
Article -
2
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial by Manmeet S. Ahluwalia, Lisa R. Rogers, Rekha Chaudhary, Herbert Newton, Ahmad Ozair, Atulya A. Khosla, Andrew B. Nixon, Bonne J. Adams, Ben K. Seon, David M. Peereboom, Charles P. Theuer
Published 2023-09-01
Article -
3
Evaluating immune response and metabolic related biomarkers pre-allogenic hematopoietic stem cell transplant in acute myeloid leukemia. by Sharareh Siamakpour-Reihani, Felicia Cao, Jing Lyu, Yi Ren, Andrew B Nixon, Jichun Xie, Amy T Bush, Mark D Starr, James R Bain, Michael J Muehlbauer, Olga Ilkayeva, Virginia Byers Kraus, Janet L Huebner, Nelson J Chao, Anthony D Sung
Published 2022-01-01
Article -
4
Glycosaminoglycan modifications of betaglycan regulate ectodomain shedding to fine-tune TGF-β signaling responses in ovarian cancer by Alex S. Choi, Laura M. Jenkins-Lane, Wade Barton, Asha Kumari, Carly Lancaster, Calen Raulerson, Hao Ji, Diego Altomare, Mark D. Starr, Regina Whitaker, Rebecca Phaeton, Rebecca Arend, Michael Shtutman, Andrew B. Nixon, Nadine Hempel, Nam Y. Lee, Karthikeyan Mythreye
Published 2024-02-01
Article -
5
A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial by Jeffrey M. Clarke, MD, Lin Gu, MS, Xiaofei F. Wang, PhD, Thomas E. Stinchcombe, MD, Marvaretta M. Stevenson, MD, Sundhar Ramalingam, MD, Afreen Shariff, MD, Jennifer Garst, MD, Andrew B. Nixon, PhD, Scott J. Antonia, MD, Jeffrey Crawford, MD, Neal E. Ready, MD, PhD
Published 2022-06-01
Article